Vildagliptin-Induced Acute Pancreatitis |
| |
| Institution: | 1. AstraZeneca, Mölndal, Sweden;2. Bristol-Myers Squibb, Princeton, NJ, USA;3. AstraZeneca, Wilmington, DE, USA;1. Department of Clinical Chemistry, University of Liege, CHU de Liège, Domaine du Sart-Tilman, 4000 Liège, Belgium;2. Department of Nephrology, Centre Hospitalier Régional de la Citadelle, Boule vard du XIIème de Ligne, 4000 Liège, Belgium;3. Centre Hospitalier du Bois de l’Abbaye et de Hesbaye, Rue Laplace, 4100 Seraing, Belgium;4. Department of Nephrology, Dialysis and Hypertension, CHU de Liège, Domaine du Sart-Tilman, 4000 Liège, Belgium;5. Department of Nephrology-Dialysis-Apheresis, Hopital Universitaire Caremeau, Nimes, France;1. Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China;2. Department of Endocrinology, China Academy of Chinese Medical Sciences, Beijing, China;3. Peking University Traditional Chinese Medicine Clinical Medical School [Xi yuan], Beijing, China;4. Department of Endocrinology, Beijing University of Chinese Medicine, Beijing, China |
| |
| Abstract: | ObjectiveTo describe the first reported case of acute pancreatitis in a patient receiving vildagliptin.MethodsWe present the clinical, biochemical, and radiographic findings of the study patient.ResultsA 61-year-old woman who presented with severe abdominal pain was found to have acute pancreatitis. This occurred 5 weeks after the commencement of vildagliptin, a dipeptidyl-peptidase 4 inhibitor, for the treatment of type 2 diabetes mellitus. The patient’s pancreatic enzymes were elevated (amylase, 1205 U/L; lipase, 8846 U/L), and abdominal computed tomography demonstrated diffuse pancreatic swelling, cyst formation, and necrosis in the body of the pancreas. In the absence of an identifiable cause for the patient’s pancreatitis, vildagliptin was considered a potential trigger. The patient recovered after vildagliptin therapy was ceased.ConclusionsAlthough incretin-based therapy effectively treats type 2 diabetes mellitus, emerging reports of acute pancreatitis in patients receiving sitagliptin and exenatide have prompted the US Food and Drug Administration to issue an alert on these drugs. This appears to be the first reported case of acute pancreatitis in a patient receiving vildagliptin, and it supports the possibility that acute pancreatitis may be a rare effect of incretin-based therapy.(Endocr Pract. 2011;17:e48-e50) |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
